In Vitro Evidence of Therapy-Induced Suppression of Prothrombotic and Proinflammatory Phenotypes in Severe COVID-19
Por:
Ventosa-Capell, H, Martinez-Sanchez, J, De Moner, B, Ramos, A, Torramade-Moix, S, Palomo, M, Moreno-Castaño, A, Riera-Escamilla, A, Fernandez, S, Tellez, A, Escolar, G, Diaz-Ricart, M and Castro, P
Publicada:
23 ene 2026
Ahead of Print:
1 ene 2026
Resumen:
Background Endothelial dysfunction is central to COVID-19 pathophysiology, contributing to vascular complications and disease progression. However, the mechanisms driving disease evolution and response to endothelial-targeted therapies remain unclear. This study characterizes endothelial activation throughout the course of acute COVID-19 and evaluates the response to potential therapeutic agents. Methods Serum samples from patients admitted due to moderate to severe COVID-19 pneumonia were prospectively collected on three study time points (+1 day, +4 days and +10 days). Human microvascular endothelial cells were cultured in medium supplemented with pooled serum within the same disease stage, with or without defibrotide, apixaban, or tocilizumab. Endothelial activation was assessed by immunofluorescence and quantitative mRNA expression of adhesion molecules, extracellular matrix (ECM) proteins, and innate immunity receptors. ECM reactivity was evaluated using a platelet adhesion assay. Intracellular signaling pathways were analyzed by immunoblotting. Results One-hundred and two patients were included. Compared to healthy donor plasma, patient plasma induced upregulation of Vascular cell adhesion molecule-1, Toll-like receptor 4, and von Willebrand factor in endothelial cells. This effect decreased over admission days and in response to drugs. Similarly, ECM reactivity was highest at admission and declined as the disease progressed. Vascular-endothelial cadherin was mildly downregulated, but its expression was unaffected by drug treatment in vitro. Defibrotide mitigated COVID-19 serum induced p38MAPK and Erk activation but enhanced Akt phosphorylation. Conclusion Serum from severe COVID-19 patients induces a proinflammatory and prothrombotic endothelial phenotype, which can be modulated by endothelial-targeted therapies. These findings support the potential clinical value of endothelial-directed treatments.
Filiaciones:
Ventosa-Capell, H:
Univ Barcelona, Barcelona, Spain
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA
Martinez-Sanchez, J:
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Hematopathol Pathol Dept, Hemostasis & Erythropathol Lab, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
:
Univ Barcelona, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
Ramos, A:
Univ Barcelona, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Torramade-Moix, S:
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Generalitat Catalunya, Dept Salut, Banc Sang & Teixits, Barcelona, Spain
Palomo, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Hosp Clin Barcelona, Biomed Diagnost Ctr, Hematol External Qual Assessment Lab, Barcelona, Spain
Riera-Escamilla, A:
Univ Autonoma Barcelona, Dept Androl Fundacio Puigvert, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Catalonia, Spain
Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Genet, Beaverton, OR USA
Fernandez, S:
Univ Barcelona, Barcelona, Spain
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Tellez, A:
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Escolar, G:
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Hematopathol Pathol Dept, Hemostasis & Erythropathol Lab, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Diaz-Ricart, M:
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Hematopathol Pathol Dept, Hemostasis & Erythropathol Lab, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Castro, P:
Univ Barcelona, Barcelona, Spain
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Inst Salud Carlos III, CIBERINFEC, Madrid, Spain
|